Novartis/$NVS
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Novartis
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Ticker
$NVS
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Basel, Switzerland
Employees
75,883
ISIN
US66987V1098
Website
Novartis Metrics
BasicAdvanced
$228B
18.18
$6.38
0.53
$2.60
2.24%
Price and volume
Market cap
$228B
Beta
0.53
52-week high
$120.92
52-week low
$96.06
Average daily volume
1.4M
Dividend rate
$2.60
Financial strength
Current ratio
0.794
Quick ratio
0.502
Long term debt to equity
60.405
Total debt to equity
81.322
Dividend payout ratio (TTM)
60.27%
Interest coverage (TTM)
16.83%
Profitability
EBITDA (TTM)
22,086
Gross margin (TTM)
75.68%
Net profit margin (TTM)
24.16%
Operating margin (TTM)
33.35%
Effective tax rate (TTM)
13.80%
Revenue per employee (TTM)
$700,000
Management effectiveness
Return on assets (TTM)
11.42%
Return on equity (TTM)
32.89%
Valuation
Price to earnings (TTM)
18.185
Price to revenue (TTM)
4.356
Price to book
4.86
Price to tangible book (TTM)
-13.26
Price to free cash flow (TTM)
15.531
Free cash flow yield (TTM)
6.44%
Free cash flow per share (TTM)
746.62%
Dividend yield (TTM)
2.24%
Forward dividend yield
2.24%
Growth
Revenue change (TTM)
11.50%
Earnings per share change (TTM)
-13.29%
3-year revenue growth (CAGR)
0.14%
10-year revenue growth (CAGR)
0.14%
3-year earnings per share growth (CAGR)
-15.93%
10-year earnings per share growth (CAGR)
-2.53%
3-year dividend per share growth (CAGR)
4.34%
10-year dividend per share growth (CAGR)
3.97%
What the Analysts think about Novartis
Analyst ratings (Buy, Hold, Sell) for Novartis stock.
Bulls say / Bears say
Novartis raised its full-year 2024 earnings forecast for the second time, driven by increased prescriptions for Entresto and Cosentyx, indicating strong product performance and market demand. (reuters.com)
The company reported a 12% increase in third-quarter sales to $11.78 billion, surpassing analyst expectations and demonstrating robust financial health. (investing.com)
Novartis' strategic focus on innovative medicines, following the spin-off of its generics division Sandoz, positions it to capitalize on higher-margin products and streamline operations. (seekingalpha.com)
The impending loss of U.S. patent protection for Entresto in 2025 poses a significant risk to Novartis' revenue stream, as generic competition could erode sales. (investing.com)
Market skepticism persists due to pipeline uncertainties and key patent expirations, leading to concerns about future revenue stability despite current strong financials. (seekingalpha.com)
The rise of tech-driven pharmaceutical companies like Vertex Pharmaceuticals is intensifying competition, potentially challenging Novartis' market position and growth prospects. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 27 May 2025.
Novartis Financial Performance
Revenues and expenses
Novartis Earnings Performance
Company profitability
Novartis News
AllArticlesVideos
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Benzinga·1 week ago
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
GlobeNewsWire·1 week ago
Novartis' Pluvicto shown to slow prostate cancer in earlier setting
Reuters·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novartis stock?
Novartis (NVS) has a market cap of $228B as of June 20, 2025.
What is the P/E ratio for Novartis stock?
The price to earnings (P/E) ratio for Novartis (NVS) stock is 18.18 as of June 20, 2025.
Does Novartis stock pay dividends?
Yes, the Novartis (NVS) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $2.59609 and the yield is 2.24%. Novartis has a payout ratio of 60.27% on a trailing twelve-month basis.
When is the next Novartis dividend payment date?
The next Novartis (NVS) dividend payment date is unconfirmed.
What is the beta indicator for Novartis?
Novartis (NVS) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.